MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
China SXT Pharmaceuticals General and Administrative Expenses 2011-2026 | SXTC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses China SXT Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 380 K | 300 K | 474 K | 580 K | 3.45 M | 2.46 M | 2.84 M | 1.77 M | 565 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.45 M | 300 K | 1.42 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Verastem
VSTM
|
81.1 M | $ 5.04 | -4.73 % | $ 349 M |  USA |
 |
VistaGen Therapeutics
VTGN
|
17.1 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Adaptive Biotechnologies Corporation
ADPT
|
72.7 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Xenon Pharmaceuticals
XENE
|
20.7 M | $ 54.48 | -1.89 % | $ 4.24 B |  Canada |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
ChemoCentryx
CCXI
|
78.9 M | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
17.9 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
557 M | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
15.9 M | $ 4.29 | -3.6 % | $ 822 M | Canada |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
20.9 M | - | -10.95 % | $ 876 K | USA |
 |
Fusion Pharmaceuticals
FUSN
|
31.2 M | - | - | $ 1.41 B | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 19.01 | -2.66 % | $ 889 M | USA |
 |
Gritstone Oncology
GRTS
|
28.8 M | - | 0.42 % | $ 213 M | USA |
 |
Завод ДИОД
DIOD
|
19.7 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
24.1 M | - | - | - | Russia |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 20.75 | -3.35 % | $ 3.44 B | USA |
 |
Aligos Therapeutics
ALGS
|
20.7 M | $ 6.66 | -5.4 % | $ 65.8 M | USA |
 |
Teligent, Inc.
TLGT
|
23.4 M | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
60.2 M | - | - | $ 2.91 B | USA |
 |
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alkermes plc
ALKS
|
222 M | $ 29.39 | -1.77 % | $ 4.84 B |  Irlanda |
 |
Cabaletta Bio
CABA
|
29.6 M | $ 2.68 | -4.96 % | $ 269 M | USA |
 |
AbbVie
ABBV
|
14 B | $ 209.4 | -0.81 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Athira Pharma
ATHA
|
26.1 M | - | - | $ 269 M | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |